Interpace Diagnostics Group, Inc. (NASDAQ:IDXG) Files An 8-K Other EventsItem 8.01. Other Events.
On July 27, 2017, Interpace Diagnostics Group, Inc. (the “Company”) issued a press release announcing that Cigna, one of the largest national health plans in the United States, has agreed to cover the Company’s ThyGenX® test for Cigna’s 15 million members nationwide, with coverage effective immediately. ThyGenX® yields high predictive value in determining the presence of cancer in thyroid nodules. A copy of the press release is attached hereto as Exhibit 99.1 and incorporated herein by reference.
Item 9.01. Financial Statements and Exhibits
(d) Exhibits
|
Exhibit Number |
Description |
| 99.1 | Press release dated July 27, 2017 |
Interpace Diagnostics Group, Inc. ExhibitEX-99.1 2 ex99-1.htm Interpace Diagnostics Announces Cigna Coverage of ThyGenX® Molecular Test Now Covered for Indeterminate Thyroid Nodules PARSIPPANY,…To view the full exhibit click here
About Interpace Diagnostics Group, Inc. (NASDAQ:IDXG)
Interpace Diagnostics Group, Inc., formerly PDI, Inc., is focused on developing and commercializing molecular diagnostic tests principally focused on early detection of high potential progressors to cancer and leveraging the latest technology and personalized medicine for patient diagnosis and management. The Company operates through molecular diagnostics segment. It offers molecular tests, such as PancraGen, which is a pancreatic cyst molecular test that can aid in pancreatic cyst diagnosis and pancreatic cancer risk assessment utilizing its PathFinder platform; ThyGenX, which assesses thyroid nodules for risk of malignancy, and ThyraMIR, which assesses thyroid nodules risk of malignancy utilizing a gene expression assay. Through its molecular diagnostics business, the Company provides diagnostic options for detecting genetic and other molecular alterations that are associated with gastrointestinal and endocrine cancers, which are focused on early detection of cancer.